Workaround erases side effects of promising cell-based cancer therapy
Stanford scientists created an odd couple: a modified version of an immune-signaling protein and a coordinately modified receptor for this protein. The two bind only to each other, easing an advanced anti-cancer therapy’s side effects.
Altering a powerful immune-signaling chemical plus its receptor on immune cells may bring a promising cancer treatment closer to the clinic, according to a study led by investigators at the Stanford University School of Medicine.
If the advance proves as beneficial in humans as in mice used in the study, which was conducted in collaboration with researchers at the University of California-Los Angeles and UC-San Francisco, then incorporating it into the experimental regimen, called adoptive cell transfer, could speed that treatment’s acceptance as a standard anti-cancer practice.
In adoptive cell transfer, immune cells called killer T cells are purified from a patient’s blood, endowed with superior tumor-recognition features via genetic engineering, and induced to proliferate. The modified cells are returned to the patient’s circulatory system, where they can efficiently and selectively destroy tumors.
But this approach is hampered by the modified T cells’ failure to continue to survive, multiply and sustain their targeted rampage for substantial amounts of time after they’ve been transferred back into the patient. That’s because the altered T cells need frequent “booster shots” of a crucial protein called interleukin-2, or IL-2, just as natural T cells do.
“IL-2 is a master regulator of the immune system and, in particular, the principal T-cell growth factor,” said Christopher Garcia, PhD, professor of molecular and cellular physiology and of structural biology, and a Howard Hughes Medical Institute investigator. “It’s responsible for T cells’ development, expansion and activation.”
Garcia is the senior author of the multidisciplinary study, published March 2 in Science. The lead author is former postdoctoral scholar Jonathan Sockolosky, PhD.
Secreted in response to threats
Produced naturally by various types of immune cells, IL-2 is secreted in response to various threats. When it binds to receptors on T cells’ surfaces, including receptors on the T cells secreting it, it spurs them to action. Deprived of this booster substance, once-active T cells become inhibited, exhausted and, ultimately, burnt out.
This applies to the modified T cells infused into cancer patients, said Garcia, who holds the Younger Family Professorship. “These bioengineered T cells need IL-2 to survive, to work and to expand in number, just as our natural ones do,” he said.
That’s fine while the T cells are outside the patient’s body. But strategies to boost the efficacy of adoptive cell transfer approaches by following up T cell infusion with intravenous IL-2 administrations have had major limitations. The reason is that the side effects provoked by substantial doses of the powerful protein — especially pulmonary edema — are so severe as to outweigh the advantages of the treatment.
The problem is that receptors for IL-2 are found not only on T cells but other immune cells that are better left inactive during cancer therapy — for instance, so-called regulatory T cells whose job is to mute the immune response after the immune system has been mobilized against a tumor or invading pathogen. Failure of the immune system to stand down can spell constant tissue-damaging inflammation and autoimmune disease. Many other types of cells in the body, such as lung cells, also harbor IL-2 receptors, Garcia said, and IL-2 can induce damaging inflammation to the tissues containing those cells.
But Garcia and his research group have found a workaround that should allow adoptive cell transfer to proceed without burnout — and without IL-2’s devastating side effects.
“We engineered a slightly tweaked version of one of IL-2’s constituent subunits so that a receptor containing this subunit can no longer bind to IL-2,” he said. “And we generated a slightly altered IL-2 molecule that can’t bind to its normal receptor.” But the modified protein and modified receptor bind with high affinity to one another. Garcia credited Sockolosky for the meticulous matchmaking that paired up this auspicious odd couple.
Using laboratory methods to snap the modified receptors onto T cells from mice, Garcia’s group showed in a series of experiments that these T cells responded to modified IL-2 exactly as natural T cells would be expected to respond to ordinary IL-2. But unmodified T cells didn’t respond to the modified IL-2 at all.
Adoptive cell therapy is on the cusp of becoming a revolutionary new approach to cancer treatment.
Next, Garcia’s team and colleagues turned to the laboratories of two of the study’s co-authors, UCSF immunologist Jeffrey Bluestone, PhD, and UCLA cancer specialist Antoni Ribas, MD. There, further disease-based experiments were conducted, including some with mice in which a well-characterized type of melanoma had been induced. Mice burdened by this highly aggressive tumor ordinarily die quickly. Adoptive cell therapy — the infusion of the mice’s own T cells after they’d been bioengineered to target that specific tumor type — followed by regular IL-2 infusions was able to arrest growth in these melanomas, but the IL-2 caused a plethora of nasty side effects mirroring those of its administration in humans: weight loss, restricted mobility, hypothermia, enlarged spleen and lymph glands, and probable death. (Mice in the study were euthanized if they became sick to the point of likely death.)
However, when T cells similarly bioengineered to attack the tumors, as well as outfitted with modified receptors responsive only to the tweaked version of IL-2, were infused into the mice and bolstered with regular doses of tweaked IL-2, they also shrunk the tumors — but without side effects. These mice’s survival was significantly improved in comparison with either untreated mice or those receiving adoptive cell transfer absent IL-2.
“Adoptive cell therapy is on the cusp of becoming a revolutionary new approach to cancer treatment,” said Garcia. “It’s undergoing explosive growth — it’s a multibillion-dollar biotechnology industry already, and it’s going to become as routine as bone marrow transplants are now. But all of the approaches in development today need IL-2, so new and better ways of delivering IL-2 are a critical unmet need. Our approach is also applicable to other important immune substances and cell types.”
Garcia said his group has now generated human odd-couple IL-2/receptor pairs that, like their mouse counterparts, bind only to one another. He is looking for collaborators in academia or industry to launch a clinical trial based on the new technology. And, he said, he believes the same approach, employed to stimulate regulatory T cells rather than killer T cells, should in principle be effective in combatting autoimmune disease. Bluestone and another study co-author, postdoctoral scholar Eleonora Trotta, PhD, are working on that approach at UCSF, Garcia noted.
Stanford’s Office of Technology Licensing has a patent pending on intellectual property associated with this work.
Other Stanford co-authors are postdoctoral scholars Lora Picton, PhD, and Akanksha Chhabra PhD; PhD; basic life science research scientist Leon Su, PhD; life science research professional Alan Le; medical student Benson George; and professor of medicine Judith Shizuru, MD.
Stanford Medicine integrates research, medical education and health care at its three institutions - Stanford University School of Medicine, Stanford Health Care (formerly Stanford Hospital & Clinics), and Lucile Packard Children's Hospital Stanford. For more information, please visit the Office of Communication & Public Affairs site at http://mednews.stanford.edu.